The stock of biOasis Technologies Inc (CVE:BTI) is a huge mover today! The stock decreased 3.45% or $0.05 on October 31, hitting $1.4. About 14,175 shares traded hands. biOasis Technologies Inc (CVE:BTI) has risen 6.00% since October 1, 2016 and is uptrending. It has outperformed by 2.53% the S&P500.
The move comes after 6 months negative chart setup for the $62.20M company. It was reported on Oct, 31 by Barchart.com. We have $1.23 PT which if reached, will make CVE:BTI worth $7.46 million less.
More notable recent biOasis Technologies Inc (CVE:BTI) news were published by: Marketwired.com which released: “biOasis Technologies Inc. to Present at BIO International Conference in San …” on May 17, 2016, also Business.Financialpost.com with their article: “Podcast: biOasis Technologies Inc CEO Rob Hutchison on how his company is …” published on March 29, 2016, Marketwired.com published: “biOasis Enters Into a License Agreement With Vaccinex Inc.” on September 21, 2016. More interesting news about biOasis Technologies Inc (CVE:BTI) were released by: Marketwired.com and their article: “biOasis Announces Grant of Stock Options” published on January 31, 2015 as well as Marketwired.com‘s news article titled: “biOasis Engages Willow Tree Group to Assist with Global Business Development …” with publication date: October 07, 2014.
biOasis Technologies Inc. is a development-stage biopharmaceutical company, which is focused on research, development and commercialization of technologies and products that are intended for the treatment of central nervous system diseases and diseases of the brain. The company has a market cap of $62.20 million. The Firm researches and develops products for diagnosis and treatment of neurological diseases and disorders. It currently has negative earnings. It is engaged in the development of its vectors Transcend and Transcendpep for the transport of therapeutic agents across the blood brain barrier (BBB).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.